Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2023 - 2026)

Recursion Pharmaceuticals (RXRX) has 4 years of Total Non-Current Liabilities data on file, last reported at $312.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 14.67% year-over-year to $312.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.7 million (down 14.67% YoY) and the FY2025 annual result came in at $341.2 million, down 16.6% from the prior year.
• Total Non-Current Liabilities eased to $312.7 million in Q1 2026, from $341.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $409.1 million in Q4 2024 to a low of $188.4 million in Q2 2024.
• A 4-year average of $304.5 million and a median of $341.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 115.01% — and 2025, when it retreated 16.6%.
• Tracing RXRX's Total Non-Current Liabilities over 4 years: stood at $190.3 million in 2023, then surged by 115.01% to $409.1 million in 2024, then dropped by 16.6% to $341.2 million in 2025, then fell by 8.34% to $312.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $312.7 million (Q1 2026), $341.2 million (Q4 2025), and $351.5 million (Q3 2025), per Business Quant data.